deltatrials
Completed PHASE3 INTERVENTIONAL 1-arm NCT00863681

BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension (PATENT-2)

Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg,1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)

Sponsor: Bayer

Conditions Hypertension, Pulmonary
Interventions Riociguat (BAY63-2521)
Updated 26 times since 2017 Last updated: Nov 2, 2023 Started: Mar 12, 2009 Primary completion: Aug 19, 2019 Completion: Aug 19, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00863681, this PHASE3 trial focuses on Hypertension, Pulmonary and remains completed. Sponsored by Bayer, it has been updated 26 times since 2009, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Mar 2018 · 8 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2020 · 13 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2023 · 35 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

26 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Dec 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Dec 2023 [monthly]

    Completed PHASE3

▶ Show 21 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE3

  2. Oct 2019 — Nov 2020 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Sep 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE3

  4. Aug 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE3

  7. May 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE3

  8. Apr 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE3

  9. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  10. Feb 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  11. Dec 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE3

  12. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE3

  13. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  14. Sep 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  15. Aug 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  16. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  17. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  18. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  19. Jul 2017 — Mar 2018 [monthly]

    Active Not Recruiting PHASE3

  20. Feb 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE3

  21. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus N, Denmark , Ankara, Turkey (Türkiye) , Auchenflower, Australia , Aurora, United States , Bangkok, Thailand , Beijing, China , Besançon, France , Boston, United States , Brest, France , Bruxelles - Brussel, Belgium and 79 more locations